Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 2Solid Tumor 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Carcinosarcoma 1Camurati-Engelmann Syndrome 1

Interventions

bintrafusp alfa protein, human 2Radiotherapy 2Cisplatin 2fresolimumab 1enzalutamide 1Sorafenib 1Paclitaxel 1LY-2157299 1Gemcitabine 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Camurati-Engelmann Syndrome × LY-2157299 × Clear all
NCT02178358 2022-02-25

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed
132 enrolled 25 charts
Gastrointestinal

Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡